Summary
Atorvastatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Glaucoma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Glaucoma. No registered clinical trial in this database tests Atorvastatin specifically in Glaucoma. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 3 publications for this pair: 1 Cochrane review, 1 meta-analysis and 1 systematic review. Publication years run from 2006 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Glaucoma ranks 339 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Progressive optic nerve damage without treatment; average visual field loss 0.5-1.0 dB/year; blindness in 10-20% without treatment; no spontaneous recovery of lost vision.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 32.0 (trials 0.0, literature 12.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 3 (1 Cochrane review, 1 meta-analysis, 1 systematic review) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | ABCA1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Atorvastatin to Glaucoma in the current OSMF trial extract.
Published literature
- Systematic review Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: A systematic reviewAhmed B, Saini N, Barathi VA et al. · Journal of controlled release : official journal of the Controlled Release Society · 2025 · PMID 40582641
- Cochrane review The Effect of Statins on Ocular Disorders: A Systematic Review of Randomized Controlled TrialsLymperopoulou C, Kandarakis SA, Tzanaki I et al. · Pharmaceuticals (Basel, Switzerland) · 2023 · PMID 37242493
- Meta-analysis The fading of reported effectiveness. A meta-analysis of randomised controlled trialsGehr BT, Weiss C, Porzsolt F · BMC medical research methodology · 2006 · PMID 16689990
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ABCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Atorvastatin approved for Glaucoma?
Atorvastatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Glaucoma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Glaucoma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Atorvastatin in clinical trials for Glaucoma?
No registered clinical trial in this database tests Atorvastatin specifically in Glaucoma. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Atorvastatin in Glaucoma?
Synthesis-level literature links Atorvastatin to Glaucoma, but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ABCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.